Latest Observability News

Neuren Pharmaceuticals has been granted a US patent for NNZ-2591 to treat Pitt Hopkins syndrome, bolstered by promising Phase 2 clinical trial results and FDA orphan drug status.

New Frontier Minerals has finalized key drill targets for Heavy Rare Earth Elements, Niobium, and Uranium at its Harts Range Project, supported by a $59,000 Northern Territory government grant and progressing towards a maiden drilling campaign.

ACDC Metals has lodged a retention licence application for its Goschen Central project in Victoria, marking a pivotal step in developing a critical minerals supply hub with strong economic prospects.

Catalina Resources is gearing up for a significant RC drilling campaign in the Central Yilgarn, following promising gold and rare earth element discoveries at its Laverton Project. The company’s expansive holdings in Western Australia reveal multiple high-grade targets with substantial exploration upside.

Peak Minerals Ltd has verified through XRD analysis that rutile constitutes over 93% of the titanium mineralisation at its Minta Rutile Project, reinforcing its status as a primary rutile province and setting the stage for further exploration.

Olympio Metals has reported visible gold in the maiden drillhole at its Paquin prospect within the Bousquet Gold Project in Quebec, signaling promising early results ahead of assays expected in mid-July.

Biotron Limited has completed the initial safety phase of its lead Hepatitis B drug in animal studies, paving the way for efficacy testing in two distinct mouse models. This milestone marks a significant step forward in the company’s antiviral drug development program.

Olympio Metals has uncovered visible gold in the first hole of its maiden drilling program at the Paquin prospect within Quebec’s prolific Bousquet Gold Project, signaling promising potential ahead of assay results due mid-July.

Warriedar Resources has successfully closed an oversubscribed Share Purchase Plan, raising $9.1 million; well above its initial $2 million target; and securing a total of $21 million in funding to accelerate exploration at its Golden Range Gold Project.

Immutep reports promising Phase I results for IMP761, a novel LAG-3 agonist antibody demonstrating significant T cell inhibition and a clean safety profile, advancing hopes for new autoimmune disease treatments.

Koonenberry Gold has reported strong assay results from its sixth drillhole at the Enmore Gold Project, confirming extended and continuous gold mineralisation. The company plans a fully funded follow-up drilling program to further expand this emerging discovery in NSW.

Nelson Resources reports promising initial rock chip assays from its Yarri Project in Western Australia, revealing high-grade gold exceeding 8 g/t and identifying new geological targets beyond known mineralisation zones.